

PRESS RELEASE

PLx Pharma Secures over \$7,500,000 in Funding to Support NSAID-PC Product Development

Houston, TX, April 6, 2007 - PLx Pharma announces the close in March 2007 of over \$6.1 million in equity financing and a National Institutes of Health grant of \$1.5 million that will provide support for further development and commercialization of the NSAID-PC technology including products PL 1100, PL 2100 and PL 3100. These products are GI safer NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen and aspirin) for both prescription and over-the-counter (OTC) uses.

Margaret McCormick, Ph.D., a partner with Integra Ventures, PLx's lead Venture Capital investor, comments "Integra is pleased with the clinical and development progress PLx Pharma has made on its GI safer product platform. The data collected thus far is compelling and demonstrates the potential PLx's products have for filling the unmet need of safer products to treat pain and inflammation. This new financing will accelerate the company's development of these programs and file an NDA on our lead product, Ibuprofen-PC."

The total funds secured by PLx Pharma included a private placement of over \$4.1 million of Convertible Preferred Stock, a \$2,000,000 award from the State of Texas Emerging Technology Fund convertible to equity and a National Institutes of Health Small Business Innovation Research and Small Business Technology Transfer award of \$1,490,000.

About PLx Pharma Inc.

PLx Pharma is developing GI safer NSAIDs that may be used for many pain and inflammation indications. The most advanced prescription products are initially intended for arthritis treatment. The Arthritis Foundation® estimates one in five Americans has arthritis. This is a substantial multi-billion dollar and growing market with a particularly compelling need in the large segment of patients at risk for NSAID induced GI injury. The lead OTC product is a GI safer aspirin.

PLx's lead product PL 1100 is a GI safer oral ibuprofen phosphatidylcholine complex (Ibuprofen-PC) utilizing a novel proprietary phospholipid technology. In a multi-centered, blinded clinical trial in osteoarthritic patients, PL 1100 provided equivalent analgesic and anti-inflammatory activity and improved GI safety in at risk patients versus unmodified ibuprofen. Long term use of an NSAID in older patients is associated with a 3-5 fold age associated risk of life threatening GI toxicity. In an at risk population, defined as over 55 years old, patients taking ibuprofen at prescription doses had a statistically significant 3.7 fold greater risk of developing multiple gastroduodenal lesions, as determined by Lanza Score using endoscopy, than patients taking PL 1100 Ibuprofen-PC.

Other products in development include PL 3100 (GI safer Naproxen-PC for prescription dose), PL 2100 (GI safer over-the-counter Aspirin-PC), PL 4100 and PL 4500 (oral and IV Indomethacin-PC) and additional NSAID-PC combinations undergoing pre-clinical testing.

Statements included in this press release may contain forward looking comments and are subject to risks and uncertainties. Actual results may differ from those indicated.

For more information please contact:

Ron Zimmerman, President

PLx Pharma Inc.
8030 El Rio
Houston, Texas 77054
Tel: 713-842-1249
www.plxpharma.com

